Nelson Vergel
Founder, ExcelMale.com
A deep dive into emerging treatments for androgenetic alopecia, alopecia areata, and scarring alopecia
Updated September 2026
Introduction
Hair-loss drug development is entering a new phase. For decades, treatment of androgenetic alopecia largely centered on minoxidil and suppression of dihydrotestosterone with finasteride or dutasteride. Alopecia areata treatment was also limited until JAK inhibitors changed the therapeutic landscape.
The investigational pipeline now reaches far beyond those approaches. Researchers are testing drugs that block or degrade the androgen receptor, reactivate dormant follicular stem cells, inhibit prolactin signaling, alter thyroid-receptor activity, manipulate Wnt signaling, change follicular metabolism, and target specific immune pathways involved in autoimmune hair loss.
This review summarizes the major investigational programs active or recently active through September 2026. The emphasis is on mechanism, development stage, human evidence, safety, and what each program could mean if later trials confirm the early findings.
Important: investigational products are not established treatments. Company press releases often appear before full peer-reviewed datasets. Hair-count changes, percentage changes, and responder analyses are not interchangeable, and results from short trials do not establish long-term durability.
1. Androgenetic Alopecia and Pattern Hair Loss
Androgenetic alopecia, or AGA, remains the largest target in hair-loss drug development. The most advanced programs fall into several categories: local androgen-receptor inhibition, androgen-receptor degradation, follicular stem-cell activation, prolactin-receptor blockade, controlled-release minoxidil, thyroid-receptor agonism, RNA interference, and regenerative signaling.
Clascoterone 5% Topical Solution, Breezula
Mechanism: topical androgen-receptor antagonist.
Development stage: Phase 3 completed in male androgenetic alopecia.
Clascoterone blocks androgen signaling at the receptor level inside scalp tissue rather than lowering circulating testosterone or DHT. The same molecule is marketed at a lower concentration for acne, while the 5% scalp formulation remains investigational for hair loss.
Two Phase 3 studies, SCALP 1 and SCALP 2, enrolled 1,465 men. Both met their target-area hair-count efficacy endpoints. Cosmo later reported 12-month follow-up showing continued improvement in participants who stayed on active treatment, while men switched from clascoterone to vehicle lost part of their prior gains.
The main clinical attraction is local androgen blockade without intentional systemic DHT suppression. This could matter to men who want an antiandrogen effect confined largely to the scalp.
Interpretation caution: promotional percentages such as a reported 539% improvement refer to relative comparisons versus vehicle in a particular analysis. They do not mean a person grew 539% more hair. Absolute hair-count changes and complete peer-reviewed Phase 3 data are more informative.
KX-826, Pyrilutamide
Mechanism: topical androgen-receptor antagonist.
Development stage: Phase 3 in China, with additional clinical development outside China.
Pyrilutamide competes with androgens at the androgen receptor. Unlike finasteride or dutasteride, its primary action is not suppression of DHT production.
Kintor reported 24-week Phase 3 results from 666 men. Mean non-vellus hair-count increases were reported as 15.33 hairs/cm2 with 1.0% twice daily, 14.46 hairs/cm2 with 0.5%, and 4.68 hairs/cm2 with vehicle. The placebo-adjusted differences were therefore about 10.65 and 9.78 hairs/cm2, respectively.
Earlier development produced mixed results, especially outside China. For this reason, complete datasets, replication, and regulatory review are more important than topline announcements alone.
A combination study has also explored KX-826 plus topical minoxidil, reflecting a broader trend toward pairing an androgen-pathway drug with a growth stimulant.
GT20029
Mechanism: topical androgen-receptor PROTAC degrader.
Development stage: Phase 2.
GT20029 is mechanistically different from clascoterone and pyrilutamide. Instead of simply blocking the androgen receptor, it uses targeted protein-degradation technology to recruit the cell's protein-disposal machinery and reduce androgen-receptor abundance.
In a randomized Phase 2 study involving 180 Chinese men, the strongest regimens produced placebo-adjusted target-area hair-count improvements of approximately 6.7 hairs/cm2 with 0.5% once daily and 7.37 hairs/cm2 with 1% twice weekly after 12 weeks. The twice-weekly 1% regimen also improved target-area hair width.
The dosing frequency is notable. If later trials confirm efficacy with infrequent application, GT20029 could address one of the practical problems with topical hair-loss treatment: long-term adherence.
PP405
Mechanism: metabolic activation of dormant hair-follicle stem cells.
Development stage: Phase 2 development, with a larger Phase 2/3 program registered.
PP405 is one of the most biologically novel programs in the pipeline. Miniaturized or inactive follicles often retain stem cells even after visible terminal hairs disappear. PP405 is designed to alter a metabolic pathway associated with stem-cell quiescence and push dormant follicular stem cells toward renewed activity.
In a 78-person Phase 2a study, men and women applied PP405 once daily for four weeks and were then followed. The company reported no detectable systemic PP405 in blood. Among men with more advanced hair loss, 31% of treated participants had greater than a 20% increase in hair density by week 8, versus 0% receiving vehicle.
The short treatment exposure followed by later measurement is one reason this program has attracted attention. The larger questions are whether new hairs become cosmetically meaningful terminal hairs, whether gains persist, and whether advanced bald scalp responds consistently across a larger population.
VDPHL01
Mechanism: extended-release oral minoxidil.
Development stage: Phase 3.
VDPHL01 does not introduce a new biological target. Instead, it attempts to turn the increasingly common off-label use of low-dose oral minoxidil into a standardized extended-release pharmaceutical product.
In a male Phase 2/3 study involving more than 500 men, Veradermics reported six-month mean non-vellus hair-count increases of 30.3 hairs/cm2 with once-daily treatment, 33.0 hairs/cm2 with twice-daily treatment, and 7.3 hairs/cm2 with placebo. Female Phase 2 data also showed mean increases of roughly 22.7 to 23.3 non-vellus hairs/cm2 at six months in active-treatment groups.
The central issue is safety. Oral minoxidil has known cardiovascular pharmacology, including blood-pressure effects, edema, tachycardia, and hypertrichosis. Extended release might change the exposure profile, but full Phase 3 safety data remain essential.
HMI-115
Mechanism: monoclonal antibody against the prolactin receptor.
Development stage: Phase 2.
HMI-115 attacks a hormonal pathway separate from androgen signaling. Prolactin and prolactin-receptor biology appear to influence human hair-follicle cycling, making the receptor a potential therapeutic target in pattern hair loss.
The product is administered by injection rather than as a scalp topical. Clinical development has included men and women with androgenetic alopecia, although the public human efficacy dataset remains limited compared with several other late-stage programs.
If prolactin-receptor blockade produces meaningful hair growth in larger trials, it would establish a new endocrine pathway for treating AGA.
ABS-201
Mechanism: long-acting prolactin-receptor antibody.
Development stage: Phase 1/2a.
ABS-201 targets the same broad pathway as HMI-115 but is engineered for prolonged exposure. Interim pharmacokinetic data reported in 2026 suggested a half-life of at least 65 days, raising the possibility of a treatment schedule involving only a few injections over six months.
Early single-dose cohorts reportedly showed no serious adverse events. Hair-growth proof-of-concept data remain the key missing piece.
TDM-105795, CU-40101
Mechanism: topical thyroid hormone receptor beta agonism.
Development stage: Phase 2.
Thyroid signaling influences anagen, follicular metabolism, and hair growth. TDM-105795 is designed to activate thyroid hormone receptor beta locally in the scalp while minimizing systemic thyroid effects.
A Phase 2 study compared topical concentrations of 0.0025% and 0.02% with vehicle over 16 weeks in men with AGA. Public efficacy information remains limited, so this program is best viewed as mechanistically interesting rather than clinically validated.
AMP-303
Mechanism: regenerative signaling approach.
Development stage: early clinical development.
Amplifica developed AMP-303 from research on signaling molecules associated with hair-follicle growth. The intended strategy differs from daily chronic topical therapy. Intradermal administration is designed to induce a regenerative or anagen-promoting response after a limited number of treatment sessions.
Published human efficacy data remain sparse, so the magnitude and durability of any benefit remain unknown.
ET-02
Mechanism: follicular stem-cell activation.
Development stage: early clinical development.
Eirion Therapeutics is developing ET-02 around pathways involved in follicular regeneration and activation. Public human efficacy data remain limited. The program is relevant because it belongs to the same broad movement as PP405: attempting to restart or rejuvenate follicles rather than only protecting them from androgens.
KB-141
Mechanism: thyroid hormone receptor beta agonist.
Development stage: early or preclinical development.
KB-141 represents another effort to exploit thyroid-receptor signaling in hair follicles while limiting systemic thyroid effects. Evidence remains far earlier than for TDM-105795.
DLQ-01
Mechanism: prostaglandin F2-alpha pathway using a latanoprost formulation.
Development stage: Phase 1/2.
Prostaglandin analogues are known to increase eyelash growth, which led to scalp-hair research. DLQ-01 is designed to improve follicular delivery of latanoprost. Clinical evidence remains early, and it has not yet established a role comparable with standard AGA drugs.
AD-303A, Topical Dutasteride
Mechanism: local 5-alpha-reductase inhibition.
Development stage: Phase 1/2a.
The goal of topical dutasteride development is simple: suppress scalp DHT while reducing systemic drug exposure. A 2026 study compares topical AD-303A with oral AD-3031 in men with AGA, focusing heavily on pharmacokinetics and pharmacodynamics.
If scalp DHT suppression is preserved while serum exposure falls, topical dutasteride could offer another way to separate local efficacy from systemic antiandrogen exposure.
OLX104C
Mechanism: RNA interference directed against androgen-receptor expression.
Development stage: early clinical development.
OLX104C uses RNA interference to reduce androgen-receptor expression rather than reducing androgen production or competing with androgens at the receptor. In principle, this could produce a longer-lasting local antiandrogen effect after intermittent administration. Human efficacy data remain early.
ADA-308
Mechanism: topical androgen-receptor antagonist.
Development stage: preclinical.
ADA-308 is being developed around potent local androgen-receptor inhibition with low systemic exposure. No convincing human efficacy dataset is yet available.
JW0061
Mechanism: GFRA1 agonism with downstream Wnt pathway activation.
Development stage: preclinical.
Wnt/beta-catenin signaling is a central regulator of follicle formation and entry into anagen. JW0061 attempts to stimulate this biology through GFRA1 signaling. The concept is strong biologically, but human efficacy remains unproven.
KY19382
Mechanism: CXXC5 inhibition and Wnt pathway activation.
Development stage: preclinical.
CXXC5 acts as a negative regulator of Wnt signaling. KY19382 is designed to remove part of that inhibitory brake. Animal data have supported hair-growth activity, but no established human efficacy evidence exists.
Dalosirvat, SM04554
Mechanism: Wnt pathway modulation.
Development stage: previously advanced into Phase 2/3 development.
Dalosirvat was one of the earlier high-profile attempts to stimulate hair growth through Wnt-related signaling and dermal-papilla biology. Development has been prolonged and uncertain. The program remains scientifically relevant because it helped test Wnt modulation in human AGA, but current development momentum appears lower than for several newer programs.
Rapamycin and Metformin-Related Approaches
Mechanism: mTOR, AMPK, cellular metabolism, and stem-cell biology.
Development stage: experimental and early translational research.
Aging follicles show changes in metabolism, mitochondrial function, and stem-cell behavior. Rapamycin-related and metformin-related approaches are being explored because mTOR and AMPK regulate cellular growth and energy sensing.
At present, neither drug should be viewed as an established hair-growth treatment. Their importance lies in the biological pathways they expose for future drug development.
2. Cell-Based and Follicle-Regeneration Programs
Some of the most ambitious hair-restoration programs are technically biologic or cell therapies rather than conventional drugs. They still belong in the pipeline because they attempt to restore follicular function rather than merely slow miniaturization.
Epibiotech Dermal Papilla Cell Therapy
Development stage: Phase 1/2.
The strategy uses autologous dermal papilla cells that are expanded and reinjected into the scalp. The objective is to rejuvenate miniaturized follicles or stimulate follicular structures capable of producing thicker hair. Clinical development remained active in 2026.
HairClone
Approach: follicle banking and dermal papilla cell expansion.
HairClone's model is to preserve follicular material while healthy follicles remain, expand relevant cells later, and reinject them into thinning scalp. This is a regenerative strategy rather than a conventional drug treatment.
OrganTech and Tsuji Follicular Primordium Technology
Approach: generation of new follicular units.
This line of research aims to manufacture follicular primordia capable of developing into functional hair follicles. It addresses the most difficult objective in hair regeneration: creation of new cycling follicular units rather than thickening or reactivating existing ones. The technology remains earlier than conventional drug development.
3. Alopecia Areata Pipeline
Alopecia areata is biologically different from androgenetic alopecia. Follicles often remain structurally capable of growing hair, but immune attack disrupts production. JAK inhibitors validated targeted immune therapy, and newer programs are testing more selective immune pathways.
Upadacitinib
Mechanism: JAK1 inhibitor.
Development stage: Phase 3 for severe alopecia areata.
Upadacitinib is already approved for several inflammatory diseases, which means its systemic pharmacology is better characterized than that of a completely new molecule. A large Phase 3 program is evaluating severe AA in adolescents and adults.
Bempikibart
Mechanism: monoclonal antibody targeting IL-7 and TSLP-related immune signaling.
Development stage: Phase 2.
Bempikibart is one of the more interesting non-JAK programs in AA. In 2026 Phase 2 SIGNAL-AA data, the company reported an average 35.3% reduction in SALT score after 36 weeks. Ten of 25 evaluable patients, or 40%, reached SALT 20 or lower, corresponding to at least 80% scalp hair coverage.
The significance is mechanistic as well as clinical. A positive larger trial would support treatment of AA through targeted cytokine biology without relying entirely on broad JAK inhibition.
LY4005130
Mechanism: investigational immune biologic.
Development stage: Phase 2.
Lilly launched an international study in adults with severe alopecia areata involving intravenous treatment. Public information on the exact mechanism and efficacy remains limited, so this program should be considered early despite its Phase 2 designation.
EQ101
Mechanism: peptide-based immune modulation targeting pathways involved in cytotoxic immune activation.
Development stage: Phase 2.
A Phase 2 proof-of-concept study enrolled adults with at least 35% scalp hair loss and administered EQ101 weekly by intravenous infusion for 24 weeks. The appeal is a potentially narrower immunologic intervention than broad JAK blockade.
Brepocitinib
Mechanism: TYK2/JAK1 inhibition.
Development stage: Phase 2 development.
Randomized data have shown meaningful SALT improvement, making brepocitinib an important proof of concept for combined JAK1/TYK2 pathway inhibition in AA. Its results also help distinguish useful immune targets from less effective selective approaches.
Deucravacitinib
Mechanism: selective TYK2 inhibition.
Development outcome: negative Phase 2 study.
In a 94-patient study, neither once-daily nor twice-daily deucravacitinib produced clinically meaningful superiority over placebo at week 24. The trial failed its primary and secondary efficacy endpoints.
Negative studies matter because they refine disease biology. The result suggests selective TYK2 inhibition alone is insufficient for many people with AA.
Etrasimod
Mechanism: S1P1/4/5 receptor modulation.
Development outcome: Phase 2 AA program discontinued.
Etrasimod produced numerical SALT improvement but did not achieve statistical superiority over placebo. Development for alopecia areata was discontinued.
Amlitelimab
Mechanism: OX40-ligand immune modulation.
Development outcome: Phase 2 completed, program terminated.
A study enrolled 166 adults with severe AA. The sponsor later terminated the program for a stated decision unrelated to safety.
Daxdilimab
Mechanism: ILT7-directed modulation or depletion of plasmacytoid dendritic cells.
Development stage: Phase 2a.
Plasmacytoid dendritic cells are major producers of type I interferons. Because interferon biology plays a role in AA, daxdilimab attempts to intervene upstream of JAK signaling by targeting one of the cell populations responsible for the inflammatory signal.
Ritlecitinib Pediatric Expansion
Ritlecitinib itself is already an approved alopecia areata therapy in older patients, so it is not an investigational molecule in that setting. Development continues in younger children, including Phase 3 evaluation in children aged 6 to under 12 years.
4. Scarring Alopecia
Scarring alopecias are more difficult because follicular structures are progressively destroyed and replaced by fibrosis. Once a follicle is lost, anti-inflammatory treatment does not recreate it. Investigational therapy therefore focuses heavily on stopping inflammatory destruction early.
Topical Delgocitinib
Mechanism: JAK1/2/3 and TYK2 inhibition.
Development stage: Phase 2 pilot.
A 2026 Mount Sinai study is testing delgocitinib 2% cream twice daily in lichen planopilaris and central centrifugal cicatricial alopecia. The pilot plans roughly 30 patients and evaluates safety, clinical activity, and molecular biomarkers over 48 weeks.
The main therapeutic objective is preservation. In scarring alopecia, prevention of permanent follicular destruction is often more realistic than regrowth from areas where follicles are already absent.
5. The Five Mechanistic Strategies Worth Watching
Androgen-receptor targeting: clascoterone, KX-826, GT20029, OLX104C, and related programs attempt to interrupt androgen signaling locally while preserving systemic androgen levels.
Follicular stem-cell reactivation: PP405, ET-02, and regenerative cell approaches attempt to restart or rejuvenate follicles instead of only slowing further miniaturization.
Prolactin-receptor inhibition: HMI-115 and ABS-201 test a hormonal pathway separate from testosterone and DHT.
Follicular metabolism and growth-cycle control: thyroid-receptor agonists, AMP-303, Wnt modulators, and metabolic approaches attempt to alter anagen entry, stem-cell activity, or follicular energy signaling.
Immune precision therapy: bempikibart, EQ101, LY4005130, daxdilimab, and selective kinase inhibitors aim to interrupt specific immune circuits involved in alopecia areata.
6. What Does 'Hair Regeneration' Really Mean?
Hair-regeneration headlines often combine biologically different outcomes. Three endpoints need to be separated:
1. Increasing the diameter of existing miniaturized hairs.
2. Returning resting or poorly productive follicles into anagen.
3. Creating new functional follicles where viable follicular units no longer exist.
Most investigational drugs aim at the first two. True de novo follicle creation has not been convincingly established as a routine drug effect in humans.
PP405 is especially interesting because its developers report growth from previously non-hair-producing areas or follicles, but larger controlled trials need to determine what those hairs become, how durable the response is, and how much advanced bald scalp truly responds.
7. What the Pipeline Means for Men Using Testosterone Replacement Therapy
Men using testosterone therapy often want to preserve systemic androgen effects while reducing androgen-driven scalp miniaturization. Several investigational approaches are directly relevant to this problem.
Local androgen-receptor antagonists such as clascoterone and pyrilutamide, receptor degradation with GT20029, and RNA interference with OLX104C all attempt to reduce androgen signaling within scalp tissue without intentionally lowering circulating testosterone.
This distinction does not prove an absence of systemic effects. Pharmacokinetic studies and long-term safety data still matter. If local exposure remains dominant, these approaches could become especially relevant for men who prefer not to lower serum DHT throughout the body.
Nonandrogen approaches such as PP405, prolactin-receptor antibodies, thyroid-receptor agonists, and regenerative strategies could also be combined conceptually with androgen-pathway treatments. Human combination data are still limited, so such combinations remain a research question rather than a treatment recommendation.
8. Where the Field Stands in September 2026
Verified fact: clascoterone, KX-826, and VDPHL01 are among the furthest-advanced pharmaceutical programs for pattern hair loss, with substantial late-stage human datasets.
Verified fact: GT20029 provides human proof of concept for targeted androgen-receptor degradation rather than simple receptor blockade.
Verified fact: PP405 has produced an early controlled human signal consistent with follicular stem-cell reactivation, but the study was small and short.
Verified fact: prolactin-receptor blockade has reached clinical development through both HMI-115 and ABS-201.
Verified fact: alopecia areata development is expanding beyond JAK inhibitors toward cytokine-directed and immune-cell-directed biologics such as bempikibart and daxdilimab.
Logical inference: combination therapy will likely remain an important research direction because different agents target different biological bottlenecks. An androgen-pathway drug plus a follicular activator is one example, but efficacy and safety need direct testing.
Unknown: whether PP405, prolactin-receptor antibodies, Wnt activators, or cell therapies will produce durable, cosmetically meaningful restoration in advanced bald scalp.
Unknown: whether company-reported topline results will remain as strong after publication of full peer-reviewed datasets and regulatory review.
9. Practical Research Watch List
For readers tracking the field, the programs most worth following over the next several trial readouts include clascoterone, KX-826, GT20029, PP405, VDPHL01, HMI-115, ABS-201, TDM-105795, OLX104C, bempikibart, and the larger regenerative-cell programs.
The key questions are straightforward: How much terminal-hair density improves, how long improvement takes, whether results persist after treatment stops, what percentage of patients respond, whether systemic exposure is truly low for scalp-directed antiandrogens, and whether safety remains acceptable over years rather than months.
References and Source Links
Cosmo Pharmaceuticals, Breezula Phase 3 and 12-month updates: Cosmo
Kintor Pharmaceutical, KX-826 clinical updates: Kintor Pharmaceutical Limited
GT20029 Phase 2 publication, PubMed PMID 41328006: https://pubmed.ncbi.nlm.nih.gov/41328006/
Pelage Pharmaceuticals, PP405 Phase 2a results: Press Releases - Pelage
Veradermics, VDPHL01 clinical updates: Dermatology Solutions | Veradermics and https://ir.veradermics.com/
ClinicalTrials.gov investigational alopecia studies: https://clinicaltrials.gov/
National Alopecia Areata Foundation clinical-study and research updates: https://www.naaf.org/
Recent AGA drug-development review, PubMed PMID 42290527: https://pubmed.ncbi.nlm.nih.gov/42290527/
Recent investigational AGA pipeline review, PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC12026576/
HairPipeline development tracker: https://hairpipeline.com/pipeline/
Editorial Note
This article is intended for education and research discussion. Investigational drugs discussed here are not approved treatments unless specifically noted otherwise. Development status changes quickly, and trial results should be interpreted from complete datasets whenever available.
Updated September 2026
Introduction
Hair-loss drug development is entering a new phase. For decades, treatment of androgenetic alopecia largely centered on minoxidil and suppression of dihydrotestosterone with finasteride or dutasteride. Alopecia areata treatment was also limited until JAK inhibitors changed the therapeutic landscape.
The investigational pipeline now reaches far beyond those approaches. Researchers are testing drugs that block or degrade the androgen receptor, reactivate dormant follicular stem cells, inhibit prolactin signaling, alter thyroid-receptor activity, manipulate Wnt signaling, change follicular metabolism, and target specific immune pathways involved in autoimmune hair loss.
This review summarizes the major investigational programs active or recently active through September 2026. The emphasis is on mechanism, development stage, human evidence, safety, and what each program could mean if later trials confirm the early findings.
Important: investigational products are not established treatments. Company press releases often appear before full peer-reviewed datasets. Hair-count changes, percentage changes, and responder analyses are not interchangeable, and results from short trials do not establish long-term durability.
1. Androgenetic Alopecia and Pattern Hair Loss
Androgenetic alopecia, or AGA, remains the largest target in hair-loss drug development. The most advanced programs fall into several categories: local androgen-receptor inhibition, androgen-receptor degradation, follicular stem-cell activation, prolactin-receptor blockade, controlled-release minoxidil, thyroid-receptor agonism, RNA interference, and regenerative signaling.
Clascoterone 5% Topical Solution, Breezula
Mechanism: topical androgen-receptor antagonist.
Development stage: Phase 3 completed in male androgenetic alopecia.
Clascoterone blocks androgen signaling at the receptor level inside scalp tissue rather than lowering circulating testosterone or DHT. The same molecule is marketed at a lower concentration for acne, while the 5% scalp formulation remains investigational for hair loss.
Two Phase 3 studies, SCALP 1 and SCALP 2, enrolled 1,465 men. Both met their target-area hair-count efficacy endpoints. Cosmo later reported 12-month follow-up showing continued improvement in participants who stayed on active treatment, while men switched from clascoterone to vehicle lost part of their prior gains.
The main clinical attraction is local androgen blockade without intentional systemic DHT suppression. This could matter to men who want an antiandrogen effect confined largely to the scalp.
Interpretation caution: promotional percentages such as a reported 539% improvement refer to relative comparisons versus vehicle in a particular analysis. They do not mean a person grew 539% more hair. Absolute hair-count changes and complete peer-reviewed Phase 3 data are more informative.
KX-826, Pyrilutamide
Mechanism: topical androgen-receptor antagonist.
Development stage: Phase 3 in China, with additional clinical development outside China.
Pyrilutamide competes with androgens at the androgen receptor. Unlike finasteride or dutasteride, its primary action is not suppression of DHT production.
Kintor reported 24-week Phase 3 results from 666 men. Mean non-vellus hair-count increases were reported as 15.33 hairs/cm2 with 1.0% twice daily, 14.46 hairs/cm2 with 0.5%, and 4.68 hairs/cm2 with vehicle. The placebo-adjusted differences were therefore about 10.65 and 9.78 hairs/cm2, respectively.
Earlier development produced mixed results, especially outside China. For this reason, complete datasets, replication, and regulatory review are more important than topline announcements alone.
A combination study has also explored KX-826 plus topical minoxidil, reflecting a broader trend toward pairing an androgen-pathway drug with a growth stimulant.
GT20029
Mechanism: topical androgen-receptor PROTAC degrader.
Development stage: Phase 2.
GT20029 is mechanistically different from clascoterone and pyrilutamide. Instead of simply blocking the androgen receptor, it uses targeted protein-degradation technology to recruit the cell's protein-disposal machinery and reduce androgen-receptor abundance.
In a randomized Phase 2 study involving 180 Chinese men, the strongest regimens produced placebo-adjusted target-area hair-count improvements of approximately 6.7 hairs/cm2 with 0.5% once daily and 7.37 hairs/cm2 with 1% twice weekly after 12 weeks. The twice-weekly 1% regimen also improved target-area hair width.
The dosing frequency is notable. If later trials confirm efficacy with infrequent application, GT20029 could address one of the practical problems with topical hair-loss treatment: long-term adherence.
PP405
Mechanism: metabolic activation of dormant hair-follicle stem cells.
Development stage: Phase 2 development, with a larger Phase 2/3 program registered.
PP405 is one of the most biologically novel programs in the pipeline. Miniaturized or inactive follicles often retain stem cells even after visible terminal hairs disappear. PP405 is designed to alter a metabolic pathway associated with stem-cell quiescence and push dormant follicular stem cells toward renewed activity.
In a 78-person Phase 2a study, men and women applied PP405 once daily for four weeks and were then followed. The company reported no detectable systemic PP405 in blood. Among men with more advanced hair loss, 31% of treated participants had greater than a 20% increase in hair density by week 8, versus 0% receiving vehicle.
The short treatment exposure followed by later measurement is one reason this program has attracted attention. The larger questions are whether new hairs become cosmetically meaningful terminal hairs, whether gains persist, and whether advanced bald scalp responds consistently across a larger population.
VDPHL01
Mechanism: extended-release oral minoxidil.
Development stage: Phase 3.
VDPHL01 does not introduce a new biological target. Instead, it attempts to turn the increasingly common off-label use of low-dose oral minoxidil into a standardized extended-release pharmaceutical product.
In a male Phase 2/3 study involving more than 500 men, Veradermics reported six-month mean non-vellus hair-count increases of 30.3 hairs/cm2 with once-daily treatment, 33.0 hairs/cm2 with twice-daily treatment, and 7.3 hairs/cm2 with placebo. Female Phase 2 data also showed mean increases of roughly 22.7 to 23.3 non-vellus hairs/cm2 at six months in active-treatment groups.
The central issue is safety. Oral minoxidil has known cardiovascular pharmacology, including blood-pressure effects, edema, tachycardia, and hypertrichosis. Extended release might change the exposure profile, but full Phase 3 safety data remain essential.
HMI-115
Mechanism: monoclonal antibody against the prolactin receptor.
Development stage: Phase 2.
HMI-115 attacks a hormonal pathway separate from androgen signaling. Prolactin and prolactin-receptor biology appear to influence human hair-follicle cycling, making the receptor a potential therapeutic target in pattern hair loss.
The product is administered by injection rather than as a scalp topical. Clinical development has included men and women with androgenetic alopecia, although the public human efficacy dataset remains limited compared with several other late-stage programs.
If prolactin-receptor blockade produces meaningful hair growth in larger trials, it would establish a new endocrine pathway for treating AGA.
ABS-201
Mechanism: long-acting prolactin-receptor antibody.
Development stage: Phase 1/2a.
ABS-201 targets the same broad pathway as HMI-115 but is engineered for prolonged exposure. Interim pharmacokinetic data reported in 2026 suggested a half-life of at least 65 days, raising the possibility of a treatment schedule involving only a few injections over six months.
Early single-dose cohorts reportedly showed no serious adverse events. Hair-growth proof-of-concept data remain the key missing piece.
TDM-105795, CU-40101
Mechanism: topical thyroid hormone receptor beta agonism.
Development stage: Phase 2.
Thyroid signaling influences anagen, follicular metabolism, and hair growth. TDM-105795 is designed to activate thyroid hormone receptor beta locally in the scalp while minimizing systemic thyroid effects.
A Phase 2 study compared topical concentrations of 0.0025% and 0.02% with vehicle over 16 weeks in men with AGA. Public efficacy information remains limited, so this program is best viewed as mechanistically interesting rather than clinically validated.
AMP-303
Mechanism: regenerative signaling approach.
Development stage: early clinical development.
Amplifica developed AMP-303 from research on signaling molecules associated with hair-follicle growth. The intended strategy differs from daily chronic topical therapy. Intradermal administration is designed to induce a regenerative or anagen-promoting response after a limited number of treatment sessions.
Published human efficacy data remain sparse, so the magnitude and durability of any benefit remain unknown.
ET-02
Mechanism: follicular stem-cell activation.
Development stage: early clinical development.
Eirion Therapeutics is developing ET-02 around pathways involved in follicular regeneration and activation. Public human efficacy data remain limited. The program is relevant because it belongs to the same broad movement as PP405: attempting to restart or rejuvenate follicles rather than only protecting them from androgens.
KB-141
Mechanism: thyroid hormone receptor beta agonist.
Development stage: early or preclinical development.
KB-141 represents another effort to exploit thyroid-receptor signaling in hair follicles while limiting systemic thyroid effects. Evidence remains far earlier than for TDM-105795.
DLQ-01
Mechanism: prostaglandin F2-alpha pathway using a latanoprost formulation.
Development stage: Phase 1/2.
Prostaglandin analogues are known to increase eyelash growth, which led to scalp-hair research. DLQ-01 is designed to improve follicular delivery of latanoprost. Clinical evidence remains early, and it has not yet established a role comparable with standard AGA drugs.
AD-303A, Topical Dutasteride
Mechanism: local 5-alpha-reductase inhibition.
Development stage: Phase 1/2a.
The goal of topical dutasteride development is simple: suppress scalp DHT while reducing systemic drug exposure. A 2026 study compares topical AD-303A with oral AD-3031 in men with AGA, focusing heavily on pharmacokinetics and pharmacodynamics.
If scalp DHT suppression is preserved while serum exposure falls, topical dutasteride could offer another way to separate local efficacy from systemic antiandrogen exposure.
OLX104C
Mechanism: RNA interference directed against androgen-receptor expression.
Development stage: early clinical development.
OLX104C uses RNA interference to reduce androgen-receptor expression rather than reducing androgen production or competing with androgens at the receptor. In principle, this could produce a longer-lasting local antiandrogen effect after intermittent administration. Human efficacy data remain early.
ADA-308
Mechanism: topical androgen-receptor antagonist.
Development stage: preclinical.
ADA-308 is being developed around potent local androgen-receptor inhibition with low systemic exposure. No convincing human efficacy dataset is yet available.
JW0061
Mechanism: GFRA1 agonism with downstream Wnt pathway activation.
Development stage: preclinical.
Wnt/beta-catenin signaling is a central regulator of follicle formation and entry into anagen. JW0061 attempts to stimulate this biology through GFRA1 signaling. The concept is strong biologically, but human efficacy remains unproven.
KY19382
Mechanism: CXXC5 inhibition and Wnt pathway activation.
Development stage: preclinical.
CXXC5 acts as a negative regulator of Wnt signaling. KY19382 is designed to remove part of that inhibitory brake. Animal data have supported hair-growth activity, but no established human efficacy evidence exists.
Dalosirvat, SM04554
Mechanism: Wnt pathway modulation.
Development stage: previously advanced into Phase 2/3 development.
Dalosirvat was one of the earlier high-profile attempts to stimulate hair growth through Wnt-related signaling and dermal-papilla biology. Development has been prolonged and uncertain. The program remains scientifically relevant because it helped test Wnt modulation in human AGA, but current development momentum appears lower than for several newer programs.
Rapamycin and Metformin-Related Approaches
Mechanism: mTOR, AMPK, cellular metabolism, and stem-cell biology.
Development stage: experimental and early translational research.
Aging follicles show changes in metabolism, mitochondrial function, and stem-cell behavior. Rapamycin-related and metformin-related approaches are being explored because mTOR and AMPK regulate cellular growth and energy sensing.
At present, neither drug should be viewed as an established hair-growth treatment. Their importance lies in the biological pathways they expose for future drug development.
2. Cell-Based and Follicle-Regeneration Programs
Some of the most ambitious hair-restoration programs are technically biologic or cell therapies rather than conventional drugs. They still belong in the pipeline because they attempt to restore follicular function rather than merely slow miniaturization.
Epibiotech Dermal Papilla Cell Therapy
Development stage: Phase 1/2.
The strategy uses autologous dermal papilla cells that are expanded and reinjected into the scalp. The objective is to rejuvenate miniaturized follicles or stimulate follicular structures capable of producing thicker hair. Clinical development remained active in 2026.
HairClone
Approach: follicle banking and dermal papilla cell expansion.
HairClone's model is to preserve follicular material while healthy follicles remain, expand relevant cells later, and reinject them into thinning scalp. This is a regenerative strategy rather than a conventional drug treatment.
OrganTech and Tsuji Follicular Primordium Technology
Approach: generation of new follicular units.
This line of research aims to manufacture follicular primordia capable of developing into functional hair follicles. It addresses the most difficult objective in hair regeneration: creation of new cycling follicular units rather than thickening or reactivating existing ones. The technology remains earlier than conventional drug development.
3. Alopecia Areata Pipeline
Alopecia areata is biologically different from androgenetic alopecia. Follicles often remain structurally capable of growing hair, but immune attack disrupts production. JAK inhibitors validated targeted immune therapy, and newer programs are testing more selective immune pathways.
Upadacitinib
Mechanism: JAK1 inhibitor.
Development stage: Phase 3 for severe alopecia areata.
Upadacitinib is already approved for several inflammatory diseases, which means its systemic pharmacology is better characterized than that of a completely new molecule. A large Phase 3 program is evaluating severe AA in adolescents and adults.
Bempikibart
Mechanism: monoclonal antibody targeting IL-7 and TSLP-related immune signaling.
Development stage: Phase 2.
Bempikibart is one of the more interesting non-JAK programs in AA. In 2026 Phase 2 SIGNAL-AA data, the company reported an average 35.3% reduction in SALT score after 36 weeks. Ten of 25 evaluable patients, or 40%, reached SALT 20 or lower, corresponding to at least 80% scalp hair coverage.
The significance is mechanistic as well as clinical. A positive larger trial would support treatment of AA through targeted cytokine biology without relying entirely on broad JAK inhibition.
LY4005130
Mechanism: investigational immune biologic.
Development stage: Phase 2.
Lilly launched an international study in adults with severe alopecia areata involving intravenous treatment. Public information on the exact mechanism and efficacy remains limited, so this program should be considered early despite its Phase 2 designation.
EQ101
Mechanism: peptide-based immune modulation targeting pathways involved in cytotoxic immune activation.
Development stage: Phase 2.
A Phase 2 proof-of-concept study enrolled adults with at least 35% scalp hair loss and administered EQ101 weekly by intravenous infusion for 24 weeks. The appeal is a potentially narrower immunologic intervention than broad JAK blockade.
Brepocitinib
Mechanism: TYK2/JAK1 inhibition.
Development stage: Phase 2 development.
Randomized data have shown meaningful SALT improvement, making brepocitinib an important proof of concept for combined JAK1/TYK2 pathway inhibition in AA. Its results also help distinguish useful immune targets from less effective selective approaches.
Deucravacitinib
Mechanism: selective TYK2 inhibition.
Development outcome: negative Phase 2 study.
In a 94-patient study, neither once-daily nor twice-daily deucravacitinib produced clinically meaningful superiority over placebo at week 24. The trial failed its primary and secondary efficacy endpoints.
Negative studies matter because they refine disease biology. The result suggests selective TYK2 inhibition alone is insufficient for many people with AA.
Etrasimod
Mechanism: S1P1/4/5 receptor modulation.
Development outcome: Phase 2 AA program discontinued.
Etrasimod produced numerical SALT improvement but did not achieve statistical superiority over placebo. Development for alopecia areata was discontinued.
Amlitelimab
Mechanism: OX40-ligand immune modulation.
Development outcome: Phase 2 completed, program terminated.
A study enrolled 166 adults with severe AA. The sponsor later terminated the program for a stated decision unrelated to safety.
Daxdilimab
Mechanism: ILT7-directed modulation or depletion of plasmacytoid dendritic cells.
Development stage: Phase 2a.
Plasmacytoid dendritic cells are major producers of type I interferons. Because interferon biology plays a role in AA, daxdilimab attempts to intervene upstream of JAK signaling by targeting one of the cell populations responsible for the inflammatory signal.
Ritlecitinib Pediatric Expansion
Ritlecitinib itself is already an approved alopecia areata therapy in older patients, so it is not an investigational molecule in that setting. Development continues in younger children, including Phase 3 evaluation in children aged 6 to under 12 years.
4. Scarring Alopecia
Scarring alopecias are more difficult because follicular structures are progressively destroyed and replaced by fibrosis. Once a follicle is lost, anti-inflammatory treatment does not recreate it. Investigational therapy therefore focuses heavily on stopping inflammatory destruction early.
Topical Delgocitinib
Mechanism: JAK1/2/3 and TYK2 inhibition.
Development stage: Phase 2 pilot.
A 2026 Mount Sinai study is testing delgocitinib 2% cream twice daily in lichen planopilaris and central centrifugal cicatricial alopecia. The pilot plans roughly 30 patients and evaluates safety, clinical activity, and molecular biomarkers over 48 weeks.
The main therapeutic objective is preservation. In scarring alopecia, prevention of permanent follicular destruction is often more realistic than regrowth from areas where follicles are already absent.
5. The Five Mechanistic Strategies Worth Watching
Androgen-receptor targeting: clascoterone, KX-826, GT20029, OLX104C, and related programs attempt to interrupt androgen signaling locally while preserving systemic androgen levels.
Follicular stem-cell reactivation: PP405, ET-02, and regenerative cell approaches attempt to restart or rejuvenate follicles instead of only slowing further miniaturization.
Prolactin-receptor inhibition: HMI-115 and ABS-201 test a hormonal pathway separate from testosterone and DHT.
Follicular metabolism and growth-cycle control: thyroid-receptor agonists, AMP-303, Wnt modulators, and metabolic approaches attempt to alter anagen entry, stem-cell activity, or follicular energy signaling.
Immune precision therapy: bempikibart, EQ101, LY4005130, daxdilimab, and selective kinase inhibitors aim to interrupt specific immune circuits involved in alopecia areata.
6. What Does 'Hair Regeneration' Really Mean?
Hair-regeneration headlines often combine biologically different outcomes. Three endpoints need to be separated:
1. Increasing the diameter of existing miniaturized hairs.
2. Returning resting or poorly productive follicles into anagen.
3. Creating new functional follicles where viable follicular units no longer exist.
Most investigational drugs aim at the first two. True de novo follicle creation has not been convincingly established as a routine drug effect in humans.
PP405 is especially interesting because its developers report growth from previously non-hair-producing areas or follicles, but larger controlled trials need to determine what those hairs become, how durable the response is, and how much advanced bald scalp truly responds.
7. What the Pipeline Means for Men Using Testosterone Replacement Therapy
Men using testosterone therapy often want to preserve systemic androgen effects while reducing androgen-driven scalp miniaturization. Several investigational approaches are directly relevant to this problem.
Local androgen-receptor antagonists such as clascoterone and pyrilutamide, receptor degradation with GT20029, and RNA interference with OLX104C all attempt to reduce androgen signaling within scalp tissue without intentionally lowering circulating testosterone.
This distinction does not prove an absence of systemic effects. Pharmacokinetic studies and long-term safety data still matter. If local exposure remains dominant, these approaches could become especially relevant for men who prefer not to lower serum DHT throughout the body.
Nonandrogen approaches such as PP405, prolactin-receptor antibodies, thyroid-receptor agonists, and regenerative strategies could also be combined conceptually with androgen-pathway treatments. Human combination data are still limited, so such combinations remain a research question rather than a treatment recommendation.
8. Where the Field Stands in September 2026
Verified fact: clascoterone, KX-826, and VDPHL01 are among the furthest-advanced pharmaceutical programs for pattern hair loss, with substantial late-stage human datasets.
Verified fact: GT20029 provides human proof of concept for targeted androgen-receptor degradation rather than simple receptor blockade.
Verified fact: PP405 has produced an early controlled human signal consistent with follicular stem-cell reactivation, but the study was small and short.
Verified fact: prolactin-receptor blockade has reached clinical development through both HMI-115 and ABS-201.
Verified fact: alopecia areata development is expanding beyond JAK inhibitors toward cytokine-directed and immune-cell-directed biologics such as bempikibart and daxdilimab.
Logical inference: combination therapy will likely remain an important research direction because different agents target different biological bottlenecks. An androgen-pathway drug plus a follicular activator is one example, but efficacy and safety need direct testing.
Unknown: whether PP405, prolactin-receptor antibodies, Wnt activators, or cell therapies will produce durable, cosmetically meaningful restoration in advanced bald scalp.
Unknown: whether company-reported topline results will remain as strong after publication of full peer-reviewed datasets and regulatory review.
9. Practical Research Watch List
For readers tracking the field, the programs most worth following over the next several trial readouts include clascoterone, KX-826, GT20029, PP405, VDPHL01, HMI-115, ABS-201, TDM-105795, OLX104C, bempikibart, and the larger regenerative-cell programs.
The key questions are straightforward: How much terminal-hair density improves, how long improvement takes, whether results persist after treatment stops, what percentage of patients respond, whether systemic exposure is truly low for scalp-directed antiandrogens, and whether safety remains acceptable over years rather than months.
References and Source Links
Cosmo Pharmaceuticals, Breezula Phase 3 and 12-month updates: Cosmo
Kintor Pharmaceutical, KX-826 clinical updates: Kintor Pharmaceutical Limited
GT20029 Phase 2 publication, PubMed PMID 41328006: https://pubmed.ncbi.nlm.nih.gov/41328006/
Pelage Pharmaceuticals, PP405 Phase 2a results: Press Releases - Pelage
Veradermics, VDPHL01 clinical updates: Dermatology Solutions | Veradermics and https://ir.veradermics.com/
ClinicalTrials.gov investigational alopecia studies: https://clinicaltrials.gov/
National Alopecia Areata Foundation clinical-study and research updates: https://www.naaf.org/
Recent AGA drug-development review, PubMed PMID 42290527: https://pubmed.ncbi.nlm.nih.gov/42290527/
Recent investigational AGA pipeline review, PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC12026576/
HairPipeline development tracker: https://hairpipeline.com/pipeline/
Editorial Note
This article is intended for education and research discussion. Investigational drugs discussed here are not approved treatments unless specifically noted otherwise. Development status changes quickly, and trial results should be interpreted from complete datasets whenever available.
